MiniMed Group Inc (NASDAQ:MMED) Receives $22.10 Average Target Price from Brokerages

MiniMed Group Inc (NASDAQ:MMED) has been assigned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $22.4545.

A number of brokerages have commented on MMED. Bank of America started coverage on MiniMed Group in a report on Tuesday. They set a “buy” rating and a $27.00 target price on the stock. Wall Street Zen raised MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Evercore initiated coverage on MiniMed Group in a research note on Tuesday. They set an “outperform” rating and a $20.00 price objective on the stock. Morgan Stanley began coverage on MiniMed Group in a research report on Tuesday. They set an “overweight” rating and a $19.00 price objective for the company. Finally, BTIG Research started coverage on shares of MiniMed Group in a research note on Tuesday. They issued a “buy” rating and a $25.00 target price for the company.

MiniMed Group Stock Down 3.2%

Shares of MMED opened at $14.01 on Tuesday. MiniMed Group has a 1-year low of $13.52 and a 1-year high of $20.48.

Key Stories Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays set an “overweight” rating with a $26 price target (~85% upside vs. current price), giving a clear bullish analyst catalyst. Article Title
• Neutral Sentiment: Goldman Sachs initiated coverage on MMED (coverage note published; no widely reported price target in the release). Article Title
• Neutral Sentiment: William Blair began coverage on MMED (initial research coverage announced). Article Title
• Neutral Sentiment: Evercore initiated coverage on MMED (coverage note released). Article Title
• Neutral Sentiment: Wells Fargo initiated coverage on MMED. Article Title
• Neutral Sentiment: Piper Sandler initiated coverage on MMED. Article Title
• Neutral Sentiment: Deutsche Bank began coverage on MMED. Article Title
• Neutral Sentiment: Citigroup initiated coverage on MMED. Article Title
• Neutral Sentiment: BTIG Research initiated coverage on MMED. Article Title
• Neutral Sentiment: Mizuho began coverage on MMED. Article Title
• Neutral Sentiment: Morgan Stanley began coverage on MMED. Article Title
• Neutral Sentiment: Bank of America initiated coverage on MMED. Article Title

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.